THE Estee Lauder Companies
THE ESTEE LAUDER COMPANIES INC.
Key figures
Period Jul 2025 to Jun 2026ConsolidatedU.S. GAAP
RevenueDisclosed
US$15.0B
Operating marginCalculated
5.2%
Net assets to total assetsCalculated
Could not be retrieved
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★☆☆☆position among all companies
5.2%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-4.0%
Capital efficiency
Could not be retrieved
Revenue and profit
Performance, financial position and capital allocation
THE Estee Lauder Companies
Recent performance trends
THE Estee Lauder Companies
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$17.7 billion | US$15.9 billion | US$15.6 billion | US$14.3 billion | US$15.0 billion |
| Operating income | US$3.2 billion | US$1.5 billion | US$1.0 billion | US$-0.8 billion | US$0.8 billion |
| Total assets | US$20.9 billion | US$23.4 billion | US$21.7 billion | US$19.9 billion | US$19.8 billion |
| Shareholders' equity | US$5.6 billion | Could not be retrieved | Could not be retrieved | Could not be retrieved | Could not be retrieved |
| Net cash provided by (used in) operating activities | US$3.0 billion | US$1.7 billion | US$2.4 billion | US$1.3 billion | US$1.8 billion |
| Net cash provided by (used in) investing activities | US$-0.9 billion | US$-3.2 billion | US$-1.0 billion | US$-0.6 billion | US$-0.5 billion |
| Net cash provided by (used in) financing activities | US$-3.0 billion | US$1.6 billion | US$-2.0 billion | US$-1.1 billion | US$-0.7 billion |
| Cash and cash equivalents | US$4.0 billion | US$4.0 billion | US$3.4 billion | US$2.9 billion | US$3.5 billion |
Revenue scale in the same industry
THE Estee Lauder Companies
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 12 companies
- 16 PPG IndustriesFY Dec 2025 US$15.9B
- 17 KenvueFY Dec 2025 US$15.1B
- 18 THE Estee Lauder CompaniesThis companyFY Jun 2026 US$15.0B
- 19 Regeneron PharmaceuticalsFY Dec 2025 US$14.3B
- 20 ViatrisFY Dec 2025 US$14.3B
- … 36 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$3.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.8 billion | Consolidated | Disclosed |
| Dividends paid | US$0.5 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$3.8 billion | Consolidated | Disclosed |
| Net sales | US$15.0 billion | Consolidated | Disclosed |
| Operating income | US$0.8 billion | Consolidated | Disclosed |
| Total assets | US$19.8 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$70.00 million | Consolidated | Disclosed |
| Operating margin | 5.2% | Consolidated | Calculated |
| Net assets to total assets | Cannot be calculated | Not applicable | Not calculated (no stockholders' equity in this year's 10-K) |
| Net margin | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |
| Return on equity | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |